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Cryoglobulinaemia is exceedingly difﬁcult to
manageandanappreciationofitsinsidiouspresen-
tation is key for diagnosis and early intervention.
Case history
A 56-year-old man presented with maculo-
papular erythematous rash bilaterally on his
lower limbs.
The erythematous macules and purpuric
papules over both his lower limbs had been
present for several months and were made worse
in cold conditions. He had joint arthralgia and
weakness and had been hepatitis C positive for
the past 25 years. He had three courses of inter-
feron therapy (including pegylated interferon
alfa) for his hepatitis C infection. During each
course of interferon therapy, the eruption on
his lower limbs became slightly better, however,
the therapy was unable to clear the hepatitis C
infection and so the erythematous markings
on his lower limbs worsened. He also had
Raynaud’s phenomenon for one year prior to
presentation.
The patient worked as a plumber and, hence,
often had to go into cold environments and deal
with cold water which exacerbated his condition
subsequently straining his ﬁnancial situation.
There were multiple erythematous macules
and purpuric papules; each <5 mm in diameter
on both lower limbs located on both the anterior
thigh and shin regions.
On general systems examination, he showed no
signs of peripheral or central neuropathy. Respir-
atory, GI and CVS examinations were unremark-
able. Urine dipstick showed the presence of
white blood cells.
Arthralgia, Raynaud’s syndrome and the
peculiar rash suggested the possibility of an
autoimmune aetiology. Autoantibody investi-
gations were ordered to exclude systemic lupus
erythematosus and scleroderma.
Since his arthralgia was exacerbated in cold
environments and due to the fact that he had hepa-
titis C, it was necessary to exclude the diagnosis of
cryoglobulinaemia. The diagnosis of cryoglobuli-
naemia is made from serum immunological
investigations. These are difﬁcult investigations to
organize and, hence, cryoglobulin testing is
poorly exploited in clinical practice.
1 The chief dif-
ﬁculty lies in ensuring that the blood sample is
maintained at a temperature of 37˚C until the
serum is separated.
2
A full blood count (FBC), urea and electrolytes
(U&E) rheumatoid factor (RF), and erythrocyte
sedimentation rate (ESR) were ordered. Urinana-
lysis was requested after urine dipstick showed
the presence of white blood cells. The lack of
neurological involvement on examination was sig-
niﬁcant since cryoglobulinaemia is associated
with cerebral ischaemia, spinal cord and cranial
nerve involvement. It was necessary to investigate
the possibility of vasculitis causing his skin rash
by ordering a skin biopsy of the affected areas.
His skin biopsy revealed extravasated red
blood cells, a number of inﬁltrating neutrophils
and nuclear fragments with superﬁcial dermis
ﬁbrinoid vessel wall necrosis using haematoxylin-
eosin stain. His serum electrophoresis conﬁrmed
the presence of cyroglobulinaemia. Although his
FBC, U&E and ESR tests were normal, his serum
contained high levels of rheumatoid factor.
3 His
urinalysis revealed a urine white cell count of 15
uL which prompted a need for renal biopsy to
explore the possibility of glomerulonephritis. The
autoantibody screen was negative.
The patient was diagnosed with leucocyto-
clastic vasculitis with type 2 cryoglobulinaemia.
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1A multidisciplinary approach was adopted
since this rare disease affects many organ
systems. A consultation was set up to review this
case. The team comprised a rheumatologist, der-
matologist, nephrologist and clinical immunolo-
gist, who discussed his management plan.
Considering the patient failed to respond to
hepatitis C therapy, immunosuppression was the
next step. Rituximab was considered as it has
been shown to be a safe and effective therapeutic
option in alleviating symptoms in such patients,
even as a ﬁrst line therapy.
4–7 A more detailed
description of possible treatments is mentioned
in the Discussion section below.
Discussion
This was a very complex case. This section will
describe some of the causes of type II cryoglobuli-
naemia in addition to the management options.
Cryoglobulinaemiahasaprevalenceof1:100,000,
reported from a study in the US.
8 It affects women
three times more than men and usually occurs in
middleage.ItismorecommoninSouthernEurope.
9
Cryoglobulinaemiaisanautoimmunedisease in
which exposure to temperatures below 37˚C causes
circulating immunoglobulins to precipitate in the
serum.
2 Warmth causes them to dissolve once
again. There are three types of cryoglobulinaemia
and they can be differentiated by clinical presen-
tation. The most common reported manifestations
of the disease are cutaneous involvement, articular
involvement and peripheral neuropathy. Renal
involvement also occurs frequently.
Table 1 describes the distinguishing features of
the three types of the condition. Types II and III are
often collectively referred to as ‘mixed’ type. The
patient in this case report was diagnosed by
virtue of his immunoserology and his clinical
presentation with palpable purpura and
co-existent hepatitis C infection. His blood
demonstrated polyclonal IgG with monoclonal
IgM, thus using Table 1 his condition is classiﬁed
as type II cryoglobulinaemia.
The main causes of cryoglobulinaemia include
familial/genetic, autoimmune, rheumatoid and
arthritis. Systemic lupus erythematosus (SLE) in
addition to the characteristic SLE-associated vascu-
litis is also a cause of this condition. The patient in
this case had a speciﬁc type of vasculitis known as
leucocytoclasticvasculitis.Leucocytoclasticvasculi-
tis is seen in cryoglobulinaemia, especially in
patients with concomitant hepatitis C infection.
Infectionisaveryimportantcauseofthisdisease
and parasites (toxoplasmosis, malaria), bacteria
(streptococcus, syphilis, Lyme disease) and fungi
(coccidiomyocosis) have all been associated with
Table 1
The distinguishing features of the three main types of cryoglobulinaemia. Types II and III are often collectively called ‘mixed
type’
Cryoglobulinaemia
type
Immunoglobulin
type
Clinical
ﬁndings
Differential
diagnosis
Frequency
10 Associations
Type I Monoclonal IgM,
(IgA and IgG
less
commonly)
Ischaemic necrosis,
abdominal pain
Multiple myeloma,
chronic lymphocustic
leukaemia,
waldenstrom
macroglobu
linaemia
25% Lympho-
proliferative
disease
Type II Polyclonal IgG
with
monoclonal
IgM
Palpable purpura,
membranoproliferative
glomerulonephritis,
arthralgias
Chronic liver disease,
infections (chronic
HCV infection, SLE,
Sjo ¨gren syndrome)
25% Hepatitis C
infection,
systemic lupus
erythematosus,
Sjo ¨gren
syndrome
Type III Polyclonal IgG
with polyclonal
IgM
Palpable purpura,
livedoid vasculitis,
arthralgias
50%
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2this disease. Viruses such as cytomegalovirus
(CMV), HIV, Epstein-Barr virus (EBV) and in par-
ticular; hepatitis A, B, and C
11 (or chronic liver
disease) are also important causes.
This patient was hepatitis C positive hence this
virus is most likely to be the major contributing
factor. The purpose of this report is to ensure prac-
titioners remain aware of the possibility of HCV
infection in patients presenting with palpable
purpura, livedo reticularis or urticaria.
12 This is
especially pertinent considering studies have
shown up to 8% of patients with a mixed cryoglo-
bulinaemia and leukocytoclastic vasculitis have
anti-HCVantibodies.
13
Less direct causes of cryoglobulinaemia such as
lymphoproliferative disorders and proliferative
glomerulonephritis should not be ruled out,
especially since there were white blood cells in
this patient’s urine.The characteristic initial symp-
toms of mixed cryoglobulinaemia are commonly
referred to as ‘Meltzer’s triad’ and consist of
purpura, arthralgia and myalgia.
1,14,15 This triad
in addition to renal involvement is more prevalent
in type II cryoglobulinaemia.
16 Renal involvement
initially presents as nephrotic syndrome with
positive protein on urine dipstick, serum hypo-
albuminaemia and oedema. This is promptly
followed by hypertension.
This patient’s urinalysis did not showa nephro-
tic syndrome presentation but did reveal a urine
white cell count of 15/uL. This is signiﬁcant as
over one-third of patients with cryoglobulinaemia
develop membrane proliferative glomerulone-
phritis on long-term follow-up with half of these
dying from renal insufﬁciency.
17 This risk is poten-
tiated by relapsing cutaneous involvement, and a
rising creatinine.
18
The delay in diagnosis of the patient’s
condition is not surprising considering the con-
dition’s polymorphism. This, too, is a pertinent
aspect this report seeks to highlight. These
patients often are referred to the specialty relating
to the predominant symptoms (Figure 1).
With regards to management, focus can be
directed to: (a) eradicate the HCV infection; (b)
to suppress the B-cell clonal expansion and cryo-
globulin production; or (c) to ameliorate symp-
toms depending on the individual case.
19 The
most effective treatment for hepatitis C virus posi-
tive cyroglobulinaemia is eradication of the under-
lying HCV infection.
20
Unfortunately, this patient failed to respond to
thetherapyforhishepatitisCinfection.Hencesup-
pression of the immune response is the next objec-
tive. Immunosuppressants (such as azathioprine
and cyclophosphamide) may be used in this case,
Figure 1
Demonstrating the myriad of possible presentations of cryoglobulinaemia and the variety of sources of
patient referral and investigation
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3however, they should be reserved until the renal
biopsy is analysed for indications of renal disease.
Patients with similar presentations of arthralgia
may receive beneﬁt from non-steroidal anti-
inﬂammatory drugs. However, if the condition
continues to worsen, then plasmapheresis will be
the logical treatment of choice. This should be fol-
lowed by concomitant corticosteroid treatment.
However, there have been no large multicentre
randomized controlled trials carried out of
plasma exchange versus placebo, or versus immu-
nosuppressive therapy.
21 As mentioned pre-
viously, Rituximab has shown promise, and
appears to be a safe and effective option.
4,6
With regards to prognosis, cryoglobulins,
arthralgia, and high levels of rheumatoid factor
are risk factors for chronic cutaneous disease.
22
The overall prognosis is poorer in men with renal
disease, widespread vasculitis liver failure, or lym-
phoproliferative disease.
23–25 Additionally, cryo-
globulinaemia patients can develop congestive
heart failure. There has been exciting new research
that has shown high circulating levels NTproBNP
(a marker for heart failure), in patients with mixed
cryoglobulinaemia and chronic HCV infection.
Routine screening of this marker in these patients
may assist in identifying subclinical cardiac dys-
function.
26,27 The quantiﬁcation of rheumatoid
factor may enhance the clinical monitoring of cryo-
globulinaemic vasculitis in HCV-infected patients
such as the one in this case.
28
The patient’s social problems and concerns in
this case report reﬂect the complex nature of the
disease. It is common for patients to be referred
between physicians for some time before the
ﬁnal diagnosis is reached and this is chieﬂy by
virtue of the multisystem nature of the condition.
A multidisciplinary team approach along with
clear patient-centred education and support are
vital in managing this difﬁcult condition and in
alleviating the patient’s concerns and anxieties.
The myriad of possible presentations make this
rare condition very elusive to successfully diag-
nose. An awareness and low threshold for investi-
gation will ensure an early diagnosis and timely
commencement of treatment.
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